Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.8 EUR | -3.60% | +7.25% | -.--% |
05-14 | Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | 10M 9.22M 13.62M | Capitalization | 1.46B 1.34B 1.99B |
---|---|---|---|---|---|
Net income 2024 * | -31M -28.58M -42.24M | Net income 2025 * | -25M -23.05M -34.06M | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.92M 78.31M 116M | Net cash position 2025 * | 49.8M 45.92M 67.85M | EV / Sales 2025 * | 141 x |
P/E ratio 2024 * |
-46.7
x | P/E ratio 2025 * |
-58
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Latest transcript on Belite Bio, Inc
1 week | +3.38% | ||
Current month | +15.05% | ||
1 month | +15.05% |
Managers | Title | Age | Since |
---|---|---|---|
Yue Hsin Lin
CEO | Chief Executive Officer | 46 | 18-03-26 |
Hao Yuan Chuang
DFI | Director of Finance/CFO | 40 | 20-10-31 |
Nathan L. Mata
CTO | Chief Tech/Sci/R&D Officer | 58 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 22-03-31 | |
Yi Ta Lue
BRD | Director/Board Member | 47 | 22-03-31 |
John Longo
BRD | Director/Board Member | 55 | 22-03-31 |
Date | Price | Change |
---|---|---|
24-05-31 | 42.8 | -3.60% |
24-05-30 | 44.4 | +2.78% |
24-05-29 | 43.2 | +5.37% |
24-05-28 | 41 | -0.49% |
24-05-27 | 41.2 | -0.48% |
Delayed Quote Börse Stuttgart, May 31, 2024 at 09:32 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.36% | 58.06B | |
-5.31% | 40.53B | |
+37.52% | 38.99B | |
+14.75% | 26.7B | |
-12.56% | 26.56B | |
-22.45% | 18.98B | |
+0.04% | 12.17B | |
+25.12% | 12B | |
+26.04% | 11.92B |
- Stock Market
- Equities
- BLTE Stock
- D01 Stock